Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oleogel-S10 in Inherited Epidermolysis Bullosa
NCT03068780Phase 3Completed
- Sponsor
- Amryt Pharma
- Start
- Mar 2017
- Primary completion
- Jun 2020
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, randomised, double-blind trial of Birch bark extract in epidermolysis bullosa (EB) (2 arms), sponsored by Amryt Pharma. Primary endpoint: Proportion of Patients With First Complete Closure of the EB Target Wound Within 45 Days of Treatment. Started Mar 2017; status: completed.
02
Drugs
Birch bark extract
03
Conditions
epidermolysis bullosa (EB)
Beyond the preview
Go deeper on NCT03068780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068780.